Diabetes and chronic kidney disease: Tragedy and challenge

Blood Purification

Volumn 22, Issue 1, 2004, Pages 130-135

  Chua, Dave Y ^a   Bakris, George L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antihypertensive agents; Cardiovascular risk; Diabetic nephropathy; Hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DATA BASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET; EXERCISE; HEMODYNAMIC MONITORING; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEINURIA; PULSE RATE; REVIEW; RISK REDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BLOOD GLUCOSE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DIURETICS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 0942289918     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074933     Document Type: Review

References (39)

1. Stamler J, Stamler R, Neaton JD: Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993;153:598-615.
2. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-18.
3. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, Moskowitz DW, Carmody SE: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995;25:587-594.
4. Chobanian A, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-2572.
5. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-661.
6. American Diabetes Association: Clinical practice recommendations 2003. Diabetes Care 2003;26(suppl 1):S1-S121.
7. Keane WF, Eknoyan G: Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 1999;33:1004-1010.
8. Ljungman S, Wikstrand J, Hartford M, Berglund G: Urinary albumin excretion - A predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens 1996;9:770-778.
9. Garg JP, Bakris GL: Microalbuminuria: Marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002;7:35-43.
10. Russo LM, Bakris GL, Comper WD: Renal handling of albumin: A critical review of basic concepts and perspective. Am J Kidney Dis 2002;39:899-919.
11. Dahl-Jorgenssen K, Bjoro T, Kierulf P, Sandvik L, Bangstad HJ, Hanssen KF: Long-term glycemic control and kidney function in insulin-dependent diabetes mellitus. Kidney Int 1992;41:920-923.
12. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995;47:1703-1720.
13. Bakris GL, Smith A: Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long acting calcium antagonists. Ann Intern Med 1996;125:201-204.
14. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS: Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 1986;8:II-127-II-134.
15. Campese VM, Praise M, Karubian F, Bigazzi R: Abnormal renal hemodynamics in black salt sensitive patients with hypertension. Hypertension 1991;18:805-813.
16. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D: ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000;58:2084-2092.
17. Estacio RO, Gifford N, Jeffers BW, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(suppl 2):B54-B64.
18. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 2000;160:685-693.
19. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393.
20. Weinberg MS, Kaperonis N, Bakris GL: How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep 2003;5:418-425.
21. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-945.
22. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
23. Hebert LA, Bain RP, Verne D, Cattran D, Whittier FC, Tolchin N, Rohde RD, Lewis EJ: Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int 1994;46:1688-1693.
24. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997;51:2-15.
25. Jafar TH, Stark PC, Schmid CH, Maschio G, de Jong PE, deZeeuw D, Shanafar S, Toto R, Levey AS; AIPRD Study Group: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 2003;139:244-252.
26. Ravid M, Neumann L, Lishner M: Plasma lipids and the progression of nephropathy in diabetes mellitus type II: Effect of ACE inhibitors. Kidney Int 1995;47:907-910.
27. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbu-minuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
28. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-1444.
29. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
30. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
31. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276:1886-1892.
32. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT). JAMA 2002;288:2981-2997.
33. The Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990;66:779-785.
34. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ: Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-2082.
35. Bakris GL, Weir MR, Dequattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-1289.
36. Kloke HJ, Branten AJ, Huysmans FP, Wetzels JF: Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers? Kidney Int 1998;53:1559-1573.
37. Koshy S, Bakris GL: Therapeutic approaches to achieve desired blood pressure goals: Focus on calcium channel blockers. Cardiovasc Drugs Ther 2000;14:295-301.
38. Tight blood pressure control and risk of macrovascular and microvascular complications in type II diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-713.
39. Otterstad JE, Ford I: The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur J Heart Fail 2002;4:501-506.